

Centrose Ranks as Top University Start-up

MADISON, WI. December 4, 2008 - Centrose, a Madison-based start-up company today announced that it has won a top ranked start-up recognition award at the National University Startups Competition which was held in Washington DC on October 2-3, 2008. Dr. James Prudent, Chief Executive Officer who presented the award winning seminar, Jon Thorson, professor at the University of Wisconsin, C. Richard Hutchinson, Chief Science Officer and emeritus professor in the Pharmaceutical Sciences Division founded the company in 2007.

Centrose was selected by the National Council of Entrepreneurial Tech Transfer in the final round of the competition at the annual University Startups Conference. Centrose was among over 400 university start-ups that were considered for the award and emerged with a top ranking after months of presentations via an online showcase platform to over 300 venture capitalists, angel investor and university judges. This inaugural competition was designed to provide a forum for exposure, education and feedback to entrepreneurs and universities on the subject of how to create top-level investment-worthy university spin-outs. The final presentations were given by a select group of 20 finalists to a crowd of over 200 distinguished business professionals and investors.

"This was a very professional and extensive process that we are very excited about winning" stated Dr. Prudent, "I think that the award solidifies our belief that Centrose has a compelling story that will continue to peek the interest of investors".

About Centrose LLC

Centrose, a Madison Wisconsin based biopharmaceutical company, is applying scientific breakthroughs in sugar chemistry to the discovery, development and commercialization of small molecule therapeutics. Centrose employs CarboConnect™ technology for the attachment of any sugar molecule to any compound. Sugars are involved in almost every aspect of biology and play fundamental roles in drug action. Several small-molecule drugs like erythromycin (a commonly used antibiotic) or doxorubicin (a commonly used anticancer) contain sugar linkages. It is the sugar linkages that bestow drug activity. Modifying existing small-molecule drugs with sugars has been shown to improve drug activity. Centrose's proprietary sugar technology enables the rapid enhancement of a wide variety of important drugs in a one-step process with manufacturing scalability. Centrose owns a broad set of patents and patent applications issued and filed by the Wisconsin Alumni Research Foundation and The Sloan Kettering Institute.

Contacts:

James Prudent, Ph.D.
Chief Executive Officer,
Centrose LLC
(608) 209-8933